AU · rank #19 · 2026-10-21
IMCD
AMSTERDAM · EUR · $6.73B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.184 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +16.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +10.36% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $105.55 |
| Market cap (USD) | $6.73B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a global distributor and formulator of specialty chemicals and food ingredients providing application laboratories, technical formulation, regulatory support, and supply-chain services.
Rationale
The quant model's positive EPS revisions across 30-, 60-, and 90-day horizons with 100% analyst agreement are supported by H1 2026 fundamental momentum, highlighted by a Q2 organic gross profit recovery to +7% and 8% constant-currency EBITA growth.
Material risks
- 1Margin compression from pricing weakness in specialty chemical markets, which contributed to a 0.3 percentage point decline in H1 2026 EBITA margin down to 10.8%.
- 2Potential disintermediation if major specialty chemical suppliers or end-customers bypass third-party distributors to internalize formulation, regulatory, and technical sales functions.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.